Navigation Links
Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
Date:6/30/2008

n drugs, concerning the risk of liver toxicity and the possibility of heart attacks.

Sangamo's ZFN technology represents a means of potentially circumventing these limitations or risks by specifically modifying only CD4 T-cells, the principal target of HIV pathology, in a one-time exposure of the cells to ZFNs. This results in permanent modification of the CCR5 protein such that HIV cannot enter and infect the cells. This approach could potentially enable the generation of a reservoir of protected CD4 T-cells that are available to fight the opportunistic infections that are characteristic of AIDS as well as HIV itself. Sangamo expects to initiate a clinical trial to evaluate this approach by the end of the year.

Data Reported in the Nature Biotechnology Paper

The reported results demonstrate that a one-time exposure to CCR5-specific ZFNs resulted in the generation of an HIV-resistant population of human primary T-cells by the permanent genetic modification of the CCR5 gene. These ZFN-modified CD4 T-cells expanded stably in HIV-infected cultures for several weeks and appeared to behave identically to untreated T-cells except that they were resistant to infection by HIV. ZFN treated primary CD4 T-cells and transformed CD4 cell lines resisted infection with R5-tropic HIV (virus that uses the CCR5 co-receptor to enter cells), resulting in enrichment of ZFN- generated CCR5-disrupted cells in the population upon long-term exposure to virus (>50 days). Importantly, in the presence of HIV, ZFN-modified CD4 T- cells also preferentially expanded in a mouse model. The modified cells were infused into mice that lack a normal immune system and thus do not reject human cells. After 33 days, the mice were sacrificed and analyzed for the presence of ZFN-modified cells. Researchers determined that ZFN-modified cells engrafted normally in the mouse and that the proportion of modified cells present at the end of the experiment was greater than two to three fold hi
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
2. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
3. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
6. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
7. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
8. Ardea Biosciences Reports Additional Positive Phase 2a Results for Lead HIV Candidate, RDEA806, Demonstrating Up to 1.9 Log Reduction in Plasma Viral Load with Once-Daily Dosing
9. Pressure BioSciences, Inc. Announces $850,000 NIH SBIR Phase II Award for the Development of a New PCT-dependent System for Improved Biomarker Discovery, Diagnostics, and Drug Discovery
10. Neurocrine Biosciences Completes Petal Study Treatment Phase for Endometriosis
11. Regado Biosciences Announces Publication in Circulation of Clinical Trial Results of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... SAN DIEGO , July 30, 2015 /PRNewswire/ ... a medical device company and manufacturer of the ... it has entered into non-exclusive Development Agreements with ... generation Tandem insulin pumps with the Dexcom G5 ... "Integrating Tandem,s next generation pump platform with ...
(Date:7/30/2015)... 30, 2015  Amgen (NASDAQ: AMGN ) ... of 2015. Key results include: , Total ... of 2014 to $5,370 million, with 6 percent ... (etanercept), Prolia ® (denosumab), Sensipar ® ... ® (denosumab). Unfavorable changes in foreign exchange ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 2Tandem Diabetes Care Announces Development Agreement with Dexcom for Integration of Future Generation CGM Systems 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 2Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 3Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 4Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 5Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 6Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 7Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 8Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 9Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 10Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 11Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 12Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 13Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 14Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 15Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 16Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 17Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 18Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 19Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 20Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 21Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 22Amgen's Second Quarter 2015 Revenues Increased 4 Percent To $5.4 Billion And Adjusted Earnings Per Share (EPS) Increased 8 Percent To $2.57 23Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... June 11, 2007 /PRNewswire/ -- GlaxoSmithKline,plc announced ... of its investigational non-peptide oral platelet growth,factor, ... that PROMACTA at 50-75mg once daily resulted ... and also,reduced bleeding in adult patients with ...
... Phase 1 Clinical Trial of SNS-595 in Acute,Leukemia ... June 11, 2007,/PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. presented,positive ... company's,anti-cancer product candidates, SNS-595 and SNS-032, at the ... Vienna,Austria. , Interim Results from Sunesis' Phase 1 ...
Cached Medicine Technology:Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 2Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 3Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 4Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 5Pivotal Phase III Trial Showed Promacta (eltrombopag olamine),Raised Platelet Counts and Reduced Bleeding in Patients With,Chronic ITP 6Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 2Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 3Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 4Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 5Sunesis Pharmaceuticals Reports Positive Data From Studies of Two,Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of,the European Hematology Association 6
(Date:7/31/2015)... ... July 31, 2015 , ... When the weather turned ... debuted their new type of sod called Leisure Time(TM) zoysia . It's nicknamed ... , To commemorate introduction of this new type of sod, Super-Sod is giving away ...
(Date:7/31/2015)... ... 2015 , ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle ... provider of Exilis non-surgical fat reduction in New York. Due to its unparalleled ... International clientele. Many patients travel to New York to get their non-surgical skin ...
(Date:7/31/2015)... ... 2015 , ... Sculpted Contours Luxury Medical Aesthetics announces the arrival of the ... released this new applicator in the United States as an upgrade to the CoolSmooth ... The original applicator required a 2 hour treatment time. The new CoolSmooth Pro ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Coco Libre ... athletes, judges, media, and VIPs at the 2015 Vans US Open of Surfing, July ... water that can claim “no added sugar” on the market, is a natural choice ...
(Date:7/31/2015)... Los Angeles, CA (PRWEB) , ... July 31, 2015 , ... ... of surgeons and cosmetic experts gathered to see if they could reach a consensus ... procedures, including breast augmentation and facelifts. Overall, the group reached 90 percent consensus on ...
Breaking Medicine News(10 mins):Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 2Health News:Cooler Coolsculpting in Atlanta: Treatments Now Twice As Fast 3Health News:Coco Libre Brings Eco-conscious Hydration to Vans US Open of Surfing 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... WASHINGTON, June 18 While Congressional debate is focused primarily ... many Americans remain concerned about how a mandate for private ... , , "We,re hearing politicians promise that ... to keep it. But what if the federal government ...
... , MUNDELEIN, Ill., June 18 Sysmex America today announced ... Award, presented by Premier Purchasing Partners, LP ... healthcare alliance . , , Premier contracts with ... 19 contracted suppliers to receive the Pinnacle Award. Winners are ...
... June 18 Vendormate, the market leader in vendor ... the role of president, effective immediately. Andy Monin, ... and developing strategic opportunities. , ... success of Vendormate, steadily guiding our processes, systems, and ...
... possible to determine which patients run a high risk of ... in patients with minimal memory impairment. This has been shown ... Sweden. The results have been published in the most ... . "The earlier we can catch Alzheimer,s disease, the ...
... millions of people each year, with costs reaching into ... challenge, Wound Care Certified professionals are becoming a growing ... The National Alliance of Wound Care (NAWC(R)), a ... credentialed over 7000 health care professionals as WCC(R)s (Wound ...
... to Vote on Merger Agreement with Pfizer - , , ... WYE ) today announced that it has filed a definitive proxy ... Meeting of Stockholders. Among other matters, stockholders will vote on ... was announced on January 26, 2009. , , ...
Cached Medicine News:Health News:Patient Advocacy Groups Urge Greater Focus on Patients' Choice and Privacy Rights in Health-Reform Debate 2Health News:Sysmex America Honored by Premier Healthcare Alliance for Exceptional Supplier Performance 2Health News:Bill Hayes Promoted to President of Vendormate 2Health News:Cerebrospinal fluid shows Alzheimer's disease deterioration much earlier 2Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 2Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 3Health News:Wyeth Files Definitive Proxy Statement and Announces Date for Annual Meeting of Stockholders 4
... designed from the ground-up with ergonomic concerns ... and most adjustable observation tube on the ... every user can adjust the microscope to ... helps the operator maintain an upright, comfortable ...
The BX41 offers an outstanding range of features and optical performance for the clinical market. With an emphasis on high-quality optics and a rigid frame, the BX41 offers improved versatility and e...
... operates with a simple click of ... Direct the mouse cursor to the ... of the slide and the magnified ... Graphic User Interface (GUI) enables one-click ...
Advanced ergonomic design allows greater comfort even after long hours of use. The focus knob and stage handle are located equidistant from the operator, permitting one-handed operation in a natural ...
Medicine Products: